Chimeric Therapeutics (AU: CHM)

Currency in AUD

Last close As at 25/01/2023

AUD0.08

−0.01 (−11.11%)

Market capitalisation

AUD27m

Australian-based Chimeric Therapeutics recently went public on the ASX. CLTX CAR T is in Phase I for the treatment of GBM. The technology may have applicability for other tumours such as melanoma. Chimeric recently in-licensed a CDH17 CAR T for use in solid tumours and the CORE-NK platform, which may have broad applicability in cancer.

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Jennifer Chow

    CEO

  • Paul Hopper

    Executive Chairman

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (2.3) (5.6) (66.5)
Relative 1.3 (8.6) (63.5)
52 week high/low A$0.2/A$0.1

Financials

Chimeric has announced that it has entered into an exclusive option agreement to license the clinically validated, off the shelf, robust, enhanced natural killer (CORE-NK) cell platform from Case Western Reserve University for the treatment of cancer. The CORE-NK platform was designed to overcome the hurdles associated with NK cell development and enables the production of large numbers of highly active universal donor NK cells that are active in the body. The company expects to rapidly move to complete full licensing of the platform.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2020A 0.0 (0.1) (0.1) (6200.80) N/A N/A
2021A 0.0 (14.8) (14.9) (8.16) N/A N/A
2022E 0.0 (14.0) (14.0) (4.19) N/A N/A
2023E 0.0 (14.5) (14.5) (4.32) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free